The report provides a detailed analysis essential for establishing a tipranavir production plant. It encompasses all critical aspects necessary for tipranavir production, including the cost of tipranavir production, tipranavir plant cost, tipranavir production costs, and the overall tipranavir production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tipranavir production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Tipranavir is an antiretroviral medication classified as a non-peptidic protease inhibitor. It is used to treat HIV-1 infection in treatment-experienced adults and children over age 2 whose strains are resistant to multiple other protease inhibitors. It works by inhibiting the HIV-1 protease enzyme, which prevents the maturation of viral particles through blocking the processing of polyproteins.
It is co-administered with low-dose ritonavir to boost its levels for efficacy. It is administered orally at a standard dose of 500 mg tipranavir with 200 mg ritonavir twice daily alongside optimised background regimens. It shows better viral suppression in clinical trials when combined with drugs like enfuvirtide. Its common side effects include diarrhoea, nausea, vomiting, stomach pain, headache, fatigue, dizziness, rash, and changes in body fat distribution.
The market for tipranavir is driven by the persistent global rise in HIV infections. The multi-drug resistant cases, along with growing awareness of advanced antiretroviral therapies contributes to its demand. The rise in ageing populations with chronic HIV needs and demand for pediatric oral formulations fuels the market.
The price competition from newer integrase inhibitors and long acting injectables like cabotegravir that offer better tolerability profiles affects industrial tipranavir procurement. The approvals by bodies like the FDA and EMA, changing raw material supply chains affecting API sourcing, and bulk purchasing dynamics in hospital formularies versus retail pharmacies impacts its sourcing. Other factors like regional disparities in reimbursement policies (like higher in the US versus generics-dominated low-income markets), and eco-friendly packaging and cold-chain logistics for stability adds to its procurement costs.
Raw Material for Tipranavir Production
According to the tipranavir production plant project report, the key raw materials used in the production of tipranavir include 1-phenylhexan-3-one, ethyl acetate and (1R,2S)-(−)-norephedrine, 4-biphenylyloxymethyl chloride.
Production Process of Tipranavir
The extensive tipranavir production cost report consists of the following major industrial production process:
- From 1-phenylhexan-3-one, ethyl acetate: The production of tipranavir starts with the optical resolution of racemic 3-hydroxy-3-(2-phenylethyl)hexanoic acid ethyl ester. It is derived from the aldol condensation of 1-phenylhexan-3-one with ethyl acetate employing (1R,2S)-(−)-norephedrine to yield the chiral acid. This is subsequently protected as the POM ester, reduced to primary alcohol, and oxidised to aldehyde. This aldehyde then participates in an aldol condensation with a chiral ketoester, followed by mesylation, malonate displacement, and decarboxylation. This is facilitated by NaHMDS to produce hydroxyester, which goes through oxidation to the corresponding ketoester, deprotection to intermediate, and cyclisation to dihydropyranone. Finally, nitro group reduction of dihydropyranone affords aniline, which is sulfonylated using 5-(trifluoromethyl)pyridine-2-sulfonyl chloride to get tipranavir.
Tipranavir is a crystalline solid, white to off-white in colour, which is characterised by low aqueous solubility. It has a molecular formula of C31H33F3N2O5S with a molecular weight of 602.7 g/mol. It shows good solubility in organic solvents like chloroform and methanol. It has high lipophilicity, indicated by a logP of around 5.13, and stability under storage at -20 °C. It exists as a single stereoisomer with 1R,6R configuration, 2 hydrogen bond donors, 5 acceptors, 11-12 rotatable bonds, and a polar surface area of 105-113 Ų. All these physical and chemical properties contribute to its usage as a potent nonpeptidic HIV protease inhibitor.
